Developer docs
API playgroundTry for free, no card

Search company profiles

Kromatid

Full company profile

uuid00004nz

Namestring
Kromatid
Legal namestring
KROMATID, Inc.
Websiteurl
kromatid.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Kromatid is a Boulder, Colorado-based contract laboratory services company that provides single-cell genomic integrity analysis to cell and gene therapy developers. Founded in 2016, the company operates the KROMASURE Platform, a suite of cytogenetic assays built on proprietary Directional Genomic Hybridization (dGH) technology and advanced fluorescent hybridization methods. The platform enables direct visualization of chromosomal integrity, detection of structural variants as small as approximately 2KB, and transgene integration mapping at single-cell resolution, addressing the limitations of bulk sequencing methods in detecting low-prevalence and complex genomic events (down to 0.1% prevalence). The platform comprises four integrated sub-products: KROMASURE Screen (whole-genome karyotyping with 20kb resolution), KROMASURE KBand (statistical G-Banding across up to 500 cells per batch), KROMASURE InSite (edit site integrity and transgene orientation), and KROMASURE PinPoint (high-throughput transgene integration analysis launched in 2025). The company also offers GLP- and GMP-compliant laboratory services supporting IND submissions and batch release testing.

Kromatid generates revenue through quote-based, project-driven laboratory services sold via direct enterprise engagement with biotech and pharma companies developing CAR-T, CAR-NK, gene therapies, iPSC-derived products, and CRISPR-edited cell therapies. Its go-to-market approach relies on direct scientific consultation rather than channel partners, supported by scientific content marketing, conference participation (notably ASGCT), webinars, white papers, and an active blog. The company emphasizes its singular 100% focus on single-cell cytogenetics as a differentiator from multi-specialty CROs. In August 2025, Kromatid closed an $8 million Series C funding round led by BroadOak Capital Partners, and in June 2026 appointed Matthew Hemstreet as Chief Executive Officer to lead the next phase of commercial scaling.

Short descriptiontext

Kromatid is a Boulder, Colorado-based contract laboratory services company providing single-cell genomic integrity analysis for cell and gene therapy developers. Its KROMASURE Platform uses proprietary directional Genomic Hybridization (dGH) to detect structural variants and map transgene integration at single-cell resolution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell cytogenetics, genomic integrity analysis, cell and gene therapy, molecular cytogenetics assays, chromosomal structural variants
Industry3 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomic Integrity Analysis Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Services (GLP/GMP)
TypeProfessional Services
Description

Kromatid generates revenue through providing contract laboratory services for genomic integrity analysis. The company offers GLP-compliant and GMP-compliant testing services supporting the full cell and gene therapy development lifecycle from research through batch release testing. Services are priced quote-based and likely follow a per-project or per-assay pricing model.

kromatid.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Kromatid provides single-cell genomic integrity analysis services and assays for cell and gene therapy developers through its proprietary KROMASURE Platform. The company offers GLP- and GMP-compliant contract laboratory services including karyotyping, edit site integrity assessment, transgene mapping, and G-Banding analysis at single-cell resolution. Services support therapy development from discovery through IND submission and batch release testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Detection of structural variants as small as 2KB
+1 more record
Product overview1 text field

Kromatid offers the KROMASURE Platform as its core product, a comprehensive genomic integrity analysis solution consisting of four integrated sub-products: KROMASURE Screen (high-sensitivity karyotyping for detecting mutations down to 20kb), KROMASURE KBand (genomic integrity G-Banding analyzing up to 500 cells with statistical benchmarking), KROMASURE InSite (dGH-based edit site integrity and transgene mapping for ~2KB resolution), and KROMASURE PinPoint (high-throughput transgene integration analysis for thousands of cells). The platform is complemented by GLP and GMP laboratory services. Together, these solutions provide single-cell genomic analysis across the entire cell and gene therapy development lifecycle from discovery through batch release.

Product and service1 record
1KROMASURE Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kromatid collaborates with a public-private-academic consortium including NIST to empower cancer genomics with industry-leading sequencing standards. The company is working with this consortium on the Genome in a Bottle program to develop reference standards for genomic analysis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BioReliance, part of MilliporeSigma, provides testing and manufacturing services for cell and gene therapies, including biosafety, viral clearance, and cell line characterization. It is a broad incumbent offering adjacent genomic and biological safety testing that competes for budget within CGT sponsors' release-testing workflows.

TypeBroad incumbent
Description

Charles River offers extensive cell and gene therapy services spanning manufacturing, safety testing, and genetic characterization through its CDMO and biologics testing divisions. It competes with Kromatid for genomic integrity work and brings scale, global footprint, and bundled service contracts.

TypeDirect peer
Description

NeoGenomics is a clinical and research cytogenetics laboratory offering karyotyping, FISH, and molecular cytogenetic services at scale. It is the most direct competitor in cytogenetics services, though its core focus is oncology diagnostics rather than CGT release testing.

TypeDirect peer
Description

CytoTest develops and supplies FISH probes and cytogenetics reagents used in research and clinical cytogenetics. It is directly comparable as a cytogenetics-focused technology provider and could compete with Kromatid's reagent-side opportunities or partner on assay development.

TypeEmerging player
Description

Bionano's optical genome mapping (OGM) platform is an emerging alternative to traditional cytogenetics for detecting structural variants and copy number changes. It represents a competing single-cell/large-molecule structural variant detection approach that could substitute for dGH in some CGT workflows.

TypeEmerging player
Description

Personalis provides ultra-sensitive genomic sequencing and analysis services, including tumor-informed assays with strong structural variant detection. It is an emerging player in CGT-adjacent genomic testing, particularly for cell therapy bioprocessing and patient monitoring.

TypeDirect peer
Description

Natera operates a high-throughput CLIA-certified laboratory performing molecular and cytogenetic testing at scale, including cell-free DNA and tumor profiling assays. It is comparable as a specialized, high-sensitivity molecular diagnostics laboratory serving complex genomic testing needs.

TypeBroad incumbent
Description

Eurofins Genomics offers a broad portfolio of genomic and molecular biology services, including custom assays, sequencing, and genotyping, with a global laboratory network. It competes for outsourced genomic testing budgets from biotech and academic customers.

TypeDirect peer
Description

REPROCELL provides stem cell, iPSC, and cell-based assay services for drug development and regenerative medicine. It is comparable as a specialized cell and gene therapy services provider with overlap in iPSC characterization, a key application area for Kromatid's KROMASURE platform.

TypeBroad incumbent
Description

Lonza is a leading global CDMO with deep cell and gene therapy manufacturing and testing capabilities, including genomic release testing for autologous and allogeneic therapies. It competes with Kromatid at the testing-services level while also serving as a potential channel partner for large sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kromatid

Genomic Integrity Analysis Serviceskromatid.com

Kromatid is a Boulder, Colorado-based contract laboratory services company providing single-cell genomic integrity analysis for cell and gene therapy developers. Its KROMASURE Platform uses proprietary directional Genomic Hybridization (dGH) to detect structural variants and map transgene integration at single-cell resolution.

What Kromatid does

Kromatid is a Boulder, Colorado-based contract laboratory services company that provides single-cell genomic integrity analysis to cell and gene therapy developers. Founded in 2016, the company operates the KROMASURE Platform, a suite of cytogenetic assays built on proprietary Directional Genomic Hybridization (dGH) technology and advanced fluorescent hybridization methods. The platform enables direct visualization of chromosomal integrity, detection of structural variants as small as approximately 2KB, and transgene integration mapping at single-cell resolution, addressing the limitations of bulk sequencing methods in detecting low-prevalence and complex genomic events (down to 0.1% prevalence). The platform comprises four integrated sub-products: KROMASURE Screen (whole-genome karyotyping with 20kb resolution), KROMASURE KBand (statistical G-Banding across up to 500 cells per batch), KROMASURE InSite (edit site integrity and transgene orientation), and KROMASURE PinPoint (high-throughput transgene integration analysis launched in 2025). The company also offers GLP- and GMP-compliant laboratory services supporting IND submissions and batch release testing.

Kromatid generates revenue through quote-based, project-driven laboratory services sold via direct enterprise engagement with biotech and pharma companies developing CAR-T, CAR-NK, gene therapies, iPSC-derived products, and CRISPR-edited cell therapies. Its go-to-market approach relies on direct scientific consultation rather than channel partners, supported by scientific content marketing, conference participation (notably ASGCT), webinars, white papers, and an active blog. The company emphasizes its singular 100% focus on single-cell cytogenetics as a differentiator from multi-specialty CROs. In August 2025, Kromatid closed an $8 million Series C funding round led by BroadOak Capital Partners, and in June 2026 appointed Matthew Hemstreet as Chief Executive Officer to lead the next phase of commercial scaling.

Kromatid firmographics

Firmographics
Name
Kromatid
Legal name
KROMATID, Inc.
Website
https://kromatid.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Kromatid is a Boulder, Colorado-based contract laboratory services company providing single-cell genomic integrity analysis for cell and gene therapy developers. Its KROMASURE Platform uses proprietary directional Genomic Hybridization (dGH) to detect structural variants and map transgene integration at single-cell resolution.
Ownership category
akta.pro rank

Kromatid industry classification

Industry
Product category
Genomic Integrity Analysis Services
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Single-cell cytogenetics
  • Genomic integrity analysis
  • Cell and gene therapy
  • Molecular cytogenetics assays
  • Chromosomal structural variants

Where Kromatid is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kromatid business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Services (GLP/GMP): Kromatid generates revenue through providing contract laboratory services for genomic integrity analysis. The company offers GLP-compliant and GMP-compliant testing services supporting the full cell and gene therapy development lifecycle from research through batch release testing. Services are priced quote-based and likely follow a per-project or per-assay pricing model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Kromatid product offering

Product offering

Core offering

Kromatid provides single-cell genomic integrity analysis services and assays for cell and gene therapy developers through its proprietary KROMASURE Platform. The company offers GLP- and GMP-compliant contract laboratory services including karyotyping, edit site integrity assessment, transgene mapping, and G-Banding analysis at single-cell resolution. Services support therapy development from discovery through IND submission and batch release testing.

Product overview

Kromatid offers the KROMASURE Platform as its core product, a comprehensive genomic integrity analysis solution consisting of four integrated sub-products: KROMASURE Screen (high-sensitivity karyotyping for detecting mutations down to 20kb), KROMASURE KBand (genomic integrity G-Banding analyzing up to 500 cells with statistical benchmarking), KROMASURE InSite (dGH-based edit site integrity and transgene mapping for ~2KB resolution), and KROMASURE PinPoint (high-throughput transgene integration analysis for thousands of cells). The platform is complemented by GLP and GMP laboratory services. Together, these solutions provide single-cell genomic analysis across the entire cell and gene therapy development lifecycle from discovery through batch release.

Differentiator

Problem solved

Functional benefit

Products and services

  • KROMASURE Platform

Quantifiable outcome

  • Detection of structural variants as small as 2KB
  • +1 more outcomes

Companies that use Kromatid

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Kromatid technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Kromatid partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • National Institute of Standards and Technology (NIST)coreStrategic or Co-development PartnerKromatid collaborates with a public-private-academic consortium including NIST to empower cancer genomics with industry-leading sequencing standards. The company is working with this consortium on the Genome in a Bottle program to develop reference standards for genomic analysis.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Kromatid competitors and assessment

Company assessment

Broad incumbents

  • BioReliance (MilliporeSigma): BioReliance, part of MilliporeSigma, provides testing and manufacturing services for cell and gene therapies, including biosafety, viral clearance, and cell line characterization. It is a broad incumbent offering adjacent genomic and biological safety testing that competes for budget within CGT sponsors' release-testing workflows.
  • Charles River Laboratories: Charles River offers extensive cell and gene therapy services spanning manufacturing, safety testing, and genetic characterization through its CDMO and biologics testing divisions. It competes with Kromatid for genomic integrity work and brings scale, global footprint, and bundled service contracts.
  • Eurofins Genomics: Eurofins Genomics offers a broad portfolio of genomic and molecular biology services, including custom assays, sequencing, and genotyping, with a global laboratory network. It competes for outsourced genomic testing budgets from biotech and academic customers.
  • Lonza Cell & Gene Technologies: Lonza is a leading global CDMO with deep cell and gene therapy manufacturing and testing capabilities, including genomic release testing for autologous and allogeneic therapies. It competes with Kromatid at the testing-services level while also serving as a potential channel partner for large sponsors.

Direct peers

  • NeoGenomics Laboratories: NeoGenomics is a clinical and research cytogenetics laboratory offering karyotyping, FISH, and molecular cytogenetic services at scale. It is the most direct competitor in cytogenetics services, though its core focus is oncology diagnostics rather than CGT release testing.
  • CytoTest: CytoTest develops and supplies FISH probes and cytogenetics reagents used in research and clinical cytogenetics. It is directly comparable as a cytogenetics-focused technology provider and could compete with Kromatid's reagent-side opportunities or partner on assay development.
  • Natera: Natera operates a high-throughput CLIA-certified laboratory performing molecular and cytogenetic testing at scale, including cell-free DNA and tumor profiling assays. It is comparable as a specialized, high-sensitivity molecular diagnostics laboratory serving complex genomic testing needs.
  • REPROCELL (now part of Rebirthel): REPROCELL provides stem cell, iPSC, and cell-based assay services for drug development and regenerative medicine. It is comparable as a specialized cell and gene therapy services provider with overlap in iPSC characterization, a key application area for Kromatid's KROMASURE platform.

Emerging players

  • Bionano Genomics: Bionano's optical genome mapping (OGM) platform is an emerging alternative to traditional cytogenetics for detecting structural variants and copy number changes. It represents a competing single-cell/large-molecule structural variant detection approach that could substitute for dGH in some CGT workflows.
  • Personalis: Personalis provides ultra-sensitive genomic sequencing and analysis services, including tumor-informed assays with strong structural variant detection. It is an emerging player in CGT-adjacent genomic testing, particularly for cell therapy bioprocessing and patient monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

Kromatid social profiles

Digital presence

Kromatid compliance and trust

Trust signal

Compliance2 records

Kromatid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kromatid leadership team

Management profile

Number of profiles

Profiles2 records

Kromatid funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kromatid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kromatid

What does Kromatid do?

Kromatid provides single-cell genomic integrity analysis services and assays for cell and gene therapy developers through its proprietary KROMASURE Platform. The company offers GLP- and GMP-compliant contract laboratory services including karyotyping, edit site integrity assessment, transgene mapping, and G-Banding analysis at single-cell resolution. Services support therapy development from discovery through IND submission and batch release testing.

Is Kromatid a public or private company?

Kromatid is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kromatid founded?

Kromatid was founded in 2016. It employs 11 to 50 people.

Where is Kromatid based?

Kromatid is headquartered in Boulder, United States, in the North America region.

How does Kromatid make money?

One revenue line is on record: laboratory Services (GLP/GMP).

Who are Kromatid's main competitors?

Broad incumbents on record are BioReliance (MilliporeSigma), Charles River Laboratories, Eurofins Genomics and Lonza Cell & Gene Technologies. Direct peers are NeoGenomics Laboratories, CytoTest, Natera and REPROCELL (now part of Rebirthel). Emerging players are Bionano Genomics and Personalis.

Does Kromatid have an API?

No public API is recorded for Kromatid.

What industry is Kromatid in?

Kromatid's product category is Genomic Integrity Analysis Services. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireKROMATID Selected as Industry Resource Partnership Program Member by the California Institute for Regenerative Medicine (CIRM)KROMATID was selected as a member of CIRM's Industry Resource Partnership program, giving CIRM-funded researchers access to its single-cell genomic structure analysis. The platform detects structural variation, chromosomal abnormalities, and genomic instability, helping developers assess cell fitness. The company aims to help awardees move beyond genomic integrity to genomic fitness.BizWestLongmont gene-analysis firm Kromatid elevates new leader – BizWestKromatid Inc., a Longmont-based gene-analysis company, has appointed Matthew Hemstreet as CEO, succeeding interim chief Terry Opgenorth. Hemstreet brings over a decade of leadership experience from Terumo Blood and Cell Technologies, Medtronic, and Covidien. The company recently closed an $8 million Series C round led by BroadOak Capital Partners to fuel expansion of its genomic analysis platforms and commercial operations.BioSpaceKROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene TherapyKROMATID appointed Matthew Hemstreet as CEO, succeeding Interim CEO Terry Opgenorth. Hemstreet, who joined as VP of Global Marketing in 2024, will focus on expanding the company's presence in cell and gene therapy and accelerating adoption of its KROMASURE platform. Opgenorth will remain on the board.citybizMatthew Hemstreet Named CEO of KROMATID as Company Targets Growth in Cell and Gene Therapy MarketKROMATID has appointed Matthew Hemstreet as chief executive officer, succeeding interim CEO Terry Opgenorth, as the company looks to expand its position in genomic integrity analysis for the cell and gene therapy industry. Hemstreet joined KROMATID in 2024 as vice president of global marketing and brings more than a decade of experience in marketing, product management, and commercial leadership from Terumo Blood and Cell Technologies, Medtronic, and Covidien. As CEO, he will focus on expanding KROMATID's presence in the global cell and gene therapy market and accelerating adoption of the company's KROMASURE platform.AijournKROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene TherapyKROMATID has appointed Matthew Hemstreet as Chief Executive Officer, succeeding Interim CEO Terry Opgenorth, who led the company through a strategic transformation focused on strengthening its market position and commercial focus. Hemstreet, who previously served as Vice President of Global Marketing, brings over a decade of leadership experience in the cell therapy and medical technology sectors, having launched more than 30 products at companies including Terumo Blood and Cell Technologies and Medtronic. The company, which provides genomic structural analysis services for cell and gene therapy developers, aims to leverage this leadership transition to expand its presence in the global cell and gene therapy market and advance its KROMASURE platform.PR NewswireKROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene TherapyKROMATID, a Boulder-based company specializing in genomic integrity analysis for the cell and gene therapy industry, announced the appointment of Matthew Hemstreet as Chief Executive Officer, succeeding Interim CEO Terry Opgenorth. Hemstreet brings over a decade of leadership experience in the cell therapy and medical technology sectors, having previously served as the company's Vice President of Global Marketing since 2024. The appointment is positioned as the next phase of the company's expansion, with Hemstreet tasked with scaling operations, strengthening strategic partnerships, and establishing genomic integrity assessment as an industry standard.PR NewswireKROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World's First Genomic Intelligence PlatformKROMATID announced it will present a breakthrough in genomic integrity benchmarking at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 15, 2026, during the Analytics and Assay Development – Biosafety session (Abstract #ASGCT1713). The company introduced what it calls the world's first genomic intelligence platform, which establishes chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies using high-depth cytogenetic analysis, enabling developers to contextualize variants and interpret structural variation against data-driven standards. CEO Terry Opgenorth stated this advancement aims to de-risk cell and gene therapy development and enable more therapies to reach market, with KROMATID available at Booth #1654 throughout the conference.BioSpaceKROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World’s First Genomic Intelligence PlatformKROMATID will present a breakthrough in genomic integrity benchmarking at ASGCT 2026, introducing chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies. The company says this enables contextual interpretation of structural variation and supports its genomic intelligence platform, which it says will de-risk cell and gene therapy development.NewswiseKROMATID to Present Breakthrough Genomic Integrity Benchmarking at ASGCT 2026, Powering the World's First Genomic Intelligence PlatformKROMATID announced it will present a new benchmarking method for genomic integrity in gene-edited cell therapies at the ASGCT 2026 Annual Meeting. The company describes this presentation as a key step in launching its proprietary genomic intelligence platform, which aims to provide integrated decision-ready insights for developers. This initiative seeks to de-risk cell and gene therapy development by offering chromosome-scale standards for evaluating structural variations.TipranksKROMATID Showcases Genomic Integrity Toolbox for CAR-NK Cell Therapies at ASGCTKROMATID is sponsoring a scientific session at the American Society for Gene & Cell Therapy Annual Meeting in Boston focused on genomic integrity assessment in CRISPR-modified CAR-NK cell therapies. The session will feature Dr. Dean A. Lee of Nationwide Children's Hospital presenting how a panel of genomic assays supported an Investigational New Drug application for a CD33 CAR-NK therapy in acute myeloid leukemia. KROMATID is positioning its genomic integrity and single-cell analysis capabilities as quality infrastructure for advanced cell therapy developers, with its VP of Platform Erin Cross also participating in the session.